Portal de Periódicos da CAPES

PROSPECTIVE REAL WORLD EVIDENCE: USE OF BRENTUXIMAB VEDOTIN AS CONSOLIDATION THERAPY AFTER AUTOLOGOUS TRANSPLANT IN HODGKIN LYMPHOMA. AN INTERIM ANALYSIS, ON BEHALF OF GATLA

2023; Wiley; Volume: 41; Issue: S2 Linguagem: Inglês

10.1002/hon.3165_526

1099-1069

Lorena Fiad, J L Altuve, A. Cerutti, Luciano Salvano, L. Guanchiale, F. Negri Aranguren, Fernando Warley, N. Kurgansky, M. Castro, Gonzalo Bentolila, E. Stemberg, Soledad Cruset, Laura Korin, R. Mariano, Pascual Pereyra, Carolina Mahuad, Astrid Pavlovsky,

Mycobacterium research and diagnosis

Introduction: Consolidation therapy with brentuximab vedotin (BV) after autologous stem cell transplant (auto-HCT) in the AETHERA trial, reported improved progression free survival (PFS) in patients with classical Hodgkin lymphoma (cHL) with high risk of relapse but no difference in OS. Few retrospective reports of this indication have been published. The aim of this study is to describe with a prospective Argentinian registry of all patients who undergo Auto-SCT, the selection criteria, outcomes and safety of BV as consolidation therapy. Methods: We prospectively enrolled relapsed/refractory (R/R) HL who underwent auto-HCT between September 2021 and March 2023 from different transplant centers in Argentina. We analyzed patients' characteristics, previous lines of treatment, response before and after transplant. We recollected information regarding factors that influenced BV indication and safety of the treatment. All patients are being followed for PFS and OS. Results: Sixty-one patients from 13 centers were reported. Twenty-eight (59%) of 47 evaluated patients received BV as consolidation therapy. Sixty-eight % of the patients treated with BV had 1 high risk criteria from the AETHERA trial, 25% had 2 and only 3% had all 3. The most frequent of these criteria was primary refractory disease, seen in 64% patients, followed by early relapsed in 36%. The median time from auto-HCT to first infusion of BV was 2.5 months (IQR 1.7–4.9). The median cycles of BV was 10.5 (IQR7.5-15-5). Of the 53 evaluable patients, 57% only received 1 salvage therapies, 24% 2 and 19% received 3 or more salvage therapies before Auto-SCT. Twenty-nine (55%) patients received BV before auto-HCT. All patients had PET CT before auto-SCT, a Deauville score (DS) of 1–3; 4; 5 was reported in 89%, 6% and 2% respectively. After auto-SCT, 86%, of 36 evaluated patients were in complete metabolic response with a DS 1–3. Fourteen patients (26%, of 53 evaluated) had an adverse event (AE). The most common were peripheral neuropathy in 13%, and infections in 6%. Of all AE, 6 (43%) were grade 1, 7 (50%) grade 2 and 1 (7%) grade 3, no grade 4 or 5 AE were reported. BV was temporarily suspended in 4 (28%) patients, and permanently discontinued in 2 (14%). Finally, 2 (14%) patients had complete resolution of the adverse event while 11 (78%) are still active. Conclusions: This is the only prospective evidence describing the acceptance and indication of consolidation therapy with BV in a patient with RR HL. Most of the indications were in patients with high-risk features according to the pivotal trial. This real world cohort includes a higher proportion of patients with complete metabolic response at time of auto-SCT compared with the AETHERA Trial. Follow-up time is still short, and recruitment continues. With a larger number of patients and longer follow up progression-free survival and overall survival will be reported. The research was funded by: GATLA received a grant from Takeda Keyword: Hodgkin lymphoma No conflicts of interests pertinent to the abstract.